Neumora Therapeutics – $250.1 Million IPO

San Diego – September 15, 2023 – Cooley advised the underwriters on the $250.1 million initial public offering of Neumora Therapeutics, a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Partners Charlie Kim, Kristin VanderPas, David Peinsipp and Denny Won led the Cooley team advising the underwriters.

Neumora sold 14,710,000 shares of its common stock, priced at $17 per share. In addition, Neumora granted the underwriters a 30-day option to purchase up to 2,206,500 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions. Neumora’s stock began trading on the Nasdaq Global Select Market on September 15, 2023, under the ticker symbol NMRA.

J.P. Morgan, BofA Securities, Stifel, Guggenheim Securities, RBC Capital Markets and William Blair are acting as joint book-running managers for the offering.

As of the closing date of this IPO, Cooley has worked on seven of eight US biotechnology IPOs raising at least $20 million in 2023.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.